-

Waypoint Capital Acquires Majority Stake in Allergy Partners

GENEVA--(BUSINESS WIRE)--Waypoint Capital (“Waypoint”) today announced that one of its affiliates has acquired a 70% stake in Allergy Partners (“Allergy Partners”), the largest U.S. group of single-specialty allergy and asthma practices. Allergy Partners will continue to be led by current Chief Executive Officer, David Brown. Terms of the transaction were not disclosed.

Allergy Partners was established in 1977 as a single-office practice in Western North Carolina and has grown to become the nation’s premier allergy and asthma services platform. Allergy Partners operates 62 practice hubs, comprising 135 physicians across 20 states. Leveraging its network of hubs and physicians, Allergy Partners facilitates over 300,000 annual patient encounters.

Waypoint Capital commented, “Allergy Partners is a clear industry leader with a strong culture of growth and innovation, which makes this an exciting opportunity for both Waypoint and Allergy Partners to maximize the existing footprint and evolve through organic and transformative initiatives. Waypoint has significant appreciation for the allergy marketplace, and looks forward to bringing its insight, and our investment capital, to support the Allergy Partners team as it works to provide its valuable service to even more patients nationwide.”

“We are excited to be partnering with Waypoint Capital as Allergy Partners looks to increase access to our services for even more patients across the country,” said David Brown. “Our mission is to be leaders in the development and delivery of high-quality health care for patients with asthma and allergic disease. Our partnership with Waypoint will further that mission as we continue to execute on our strategic initiatives, further build our vast care network, and promote continued research and innovation in the field of allergy and asthma care.”

McDermott Will & Emery acted as legal counsel and SVB Leerink acted as exclusive financial advisor to Waypoint.

About Waypoint Capital

Waypoint is an entrepreneurial private investment firm that partners with sophisticated capital to deliver exceptional value over the generations.

Waypoint oversees growth-orientated operating businesses and partners with asset managers, always with an "active owner" philosophy. Waypoint’s approach combines the multi-generational family values of its founders, a true entrepreneurial mindset, alongside institutional private equity disciplines.

In addition to seeding, acquiring and building asset managers in Healthcare, Technology, Ventures, Private Equity, Real Estate, Infrastructure, Credit, Hedge Funds and Public Securities, Waypoint will continue to drive expansion by growing new operating businesses in transformative industries.

Building on our heritage, Life Sciences and Healthcare is an important focus for such operating businesses, alongside certain other sectors exposed to long-term secular trends.

Waypoint’s other USA holdings include Gurnet Point Capital (www.gurnetpointcapital.com), a unique healthcare fund which invests long-term capital to enable a new generation of companies to grow and to unlock innovative and transformational healthcare solutions.

www.waypointcapital.net

Contacts

Media:
Tom Johnson/Blair Hennessy
(212) 371-5999
tbj@abmac.com/bth@abmac.com

Waypoint Capital


Release Summary
Waypoint Capital Acquires Majority Stake in Allergy Partners
Release Versions

Contacts

Media:
Tom Johnson/Blair Hennessy
(212) 371-5999
tbj@abmac.com/bth@abmac.com

More News From Waypoint Capital

Boston Pharmaceuticals Appoints Dr. Sophie Kornowski as Chair of its Board of Directors and Acting Chief Executive

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals, a clinical stage biopharmaceutical company, today announced the appointment of Dr. Sophie Kornowski as Chair of its Board of Directors and Acting Chief Executive Officer, effective immediately. Dr. Kornowski succeeds interim Co-CEOs Dr. Joanne T. Beck and Dr. Craig T. Basson, who will continue in their positions as Chief Operations Officer and Chief Medical Officer, respectively. Since 2018, Sophie Kornowski has been a partner at Gurnet...

Gurnet Point Capital Names David Moore Partner

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gurnet Point Capital (“Gurnet Point”), a private investment firm focused on health care, announced today that David Moore has been appointed as a Partner of the firm. Mr. Moore, who brings a proven track record of success with both large pharmaceutical and small biotech companies, joins Gurnet Point from Roivant Sciences, a biopharmaceutical drug development company, where he served as Chief Executive Officer of one of its infectious diseases businesses. He al...

Waypoint Capital Appoints Elias Zerhouni to Board of Directors

GENEVA--(BUSINESS WIRE)--Waypoint Capital, the business enterprise for investments associated with the Bertarelli Family, today announced the appointment of Elias Zerhouni, M.D., a world-renowned physician-scientist, to its Board of Directors, effective immediately. Dr. Zerhouni is Professor Emeritus of Radiology and Biomedical Engineering at the Johns Hopkins University, and was most recently the President, Global Research and Development for Sanofi from January 2011 to July 2018. Dr. Zerhouni...
Back to Newsroom